Home
Clinical Resources Search
PQI: VEGF Inhibitor-Induced Hypertension

VEGF Inhibitor-Induced Hypertension

Download PQI pdf 0.18MB

Last Updated: May 28, 2024

By: Sarah Gillaspie PharmD/MPH | Sarah Khaddage PharmD | Erin Zacholski PharmD, BCOP | Kyle Zacholski PharmD, BCOP

About this PQI

This document will address effective practices for the management of vascular endothelial growth factor inhibitors (VEGFIs) induced hypertension (HTN).

How to Use a Positive Quality Intervention (PQI)

Essentially, it’s a tool to improve patient care by sharing best practices in oncology care. Consider this standardized, peer-review clinical guidance to oncology healthcare teams, enabling you and your team to consistently deliver high-quality care to your patients.

Find a PQI

Find Similar Resources

All Resources

PQI PQI in Action PQI Podcast Toolkit Treatment Support Kit Video Ovarian Avastin Bevacizumab Cabometyx Cabozantinib Iclusig Lynparza Nexavar Olaparib Ponatinib Regorafenib Sorafenib Stivarga

PQI

PQI: Ibrutinib Dosing Optimization

Author: Nick Bouchard, PharmD | Danielle Maciorowski, PharmD

Frequently Searched

Supported by

VEGF Inhibitor-Induced Hypertension

About this PQI

How to Use a Positive Quality Intervention (PQI)

Find Similar Resources

PQI: Ibrutinib Dosing Optimization

PQI: Zanubrutinib (Brukinsa®) Patient Selection and Management

PQI: Zanubrutinib (Brukinsa ®) treatment for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

PQI: Vorasidenib (Voranigo®)

PQI in Action: Tepotinib (Tepmetko®) for Non-Small Cell Lung Cancerwith MET Exon 14 Alterations

PQI in Action: Siltuximab (Sylvant®) in Patients with Idiopathic Multicentric Castleman Disease

PQI in Action: Isatuximab-irfc (Sarclisa®) in 1q21 Gain or Amplifications in Relapsed/Refractory Multiple Myeloma

PQI in Action: Adagrasib (Krazati®)

The PQI Podcast S3 Ep 11: Moffitt Clinical Pharmacy Program

The PQI Podcast S3 Ep 12: Health Disparities in Cancer Screenings

The PQI Podcast S3 Ep 13: The Importance of the Multidisciplinary Team

The PQI Podcast S3 Ep 14: The Venetoclax PQI and AML Updates

Readiness Tracker

Treatment Support Kit: Abemaciclib

Treatment Support Kit: Temozolomide

Treatment Support Kit: Tivozanib

Treatment Support Kit: Regorafenib

Video: BRUKINSA® (Zanubrutinib) for Treatment of Relapsed or Refractory Marginal Zone Lymphoma

Video: BRUKINSA® (Zanubrutinib) for Treatment of Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Video: BRUKINSA® (Zanubrutinib) for Treatment of Mantle Cell Lymphoma

Video: BRUKINSA® (Zanubrutinib) for Treatment of Waldenstrom’s Macroglobulinemia

PQI: Use of Rucaparib (Rubraca®) and Indications

PQI: PARP Inhibitor Eligibility in Ovarian Cancer

PQI: Olaparib (Lynparza®) Expansion with Bevacizumab (Avastin®)

PQI: Olaparib (Lynparza®) Clinical Management

PQI: Olaparib (Lynparza®) Expansion with Bevacizumab (Avastin®)

PQI: Olaparib (Lynparza®) Expansion with Bevacizumab (Avastin®)

Treatment Support Kit: Cabozantinib

PQI: Cabozantinib (Cabometyx®)

Treatment Support Kit: Cabozantinib

PQI: Cabozantinib (Cabometyx®)

PQI: Ponatinib (Iclusig®) Patient Management

PQI: PARP Inhibitor Eligibility in Ovarian Cancer

PQI: Olaparib (Lynparza®) Expansion with Bevacizumab (Avastin®)

PQI: Olaparib (Lynparza®) Clinical Management

PQI: Olaparib (Lynparza®) Adverse Event Management

PQI: Sorafenib (Nexavar®) for the Treatment of Hepatocellular Carcinoma and Transition to Second-line Regorafenib (Stivarga®)

PQI: PARP Inhibitor Eligibility in Ovarian Cancer

PQI: Olaparib (Lynparza®) Expansion with Bevacizumab (Avastin®)

PQI: Olaparib (Lynparza®) Clinical Management

PQI: Olaparib (Lynparza®) Adverse Event Management

PQI: Ponatinib (Iclusig®) Patient Management

PQI: Sorafenib (Nexavar®) for the Treatment of Hepatocellular Carcinoma and Transition to Second-line Regorafenib (Stivarga®)

PQI: Regorafenib (Stivarga®) in the Treatment of Hepatocellular Carcinoma

PQI: Regorafenib (Stivarga®) in Metastatic Colorectal Cancer

Treatment Support Kit: Regorafenib

PQI: Sorafenib (Nexavar®) for the Treatment of Hepatocellular Carcinoma and Transition to Second-line Regorafenib (Stivarga®)

PQI: Sorafenib (Nexavar®) for the Treatment of Hepatocellular Carcinoma and Transition to Second-line Regorafenib (Stivarga®)

PQI: Regorafenib (Stivarga®) in the Treatment of Hepatocellular Carcinoma

PQI: Regorafenib (Stivarga®) in Metastatic Colorectal Cancer

Treatment Support Kit: Regorafenib

The PQI Podcast S3 Ep 11: Moffitt Clinical Pharmacy Program

The PQI Podcast S3 Ep 12: Health Disparities in Cancer Screenings

The PQI Podcast S3 Ep 13: The Importance of the Multidisciplinary Team

The PQI Podcast S3 Ep 14: The Venetoclax PQI and AML Updates